Skip to contentT
Travere Therapeutics, Inc.
T
TVTXTravere Therapeutics, Inc. Q4 2020 · 10-K
Revenue$50.98M$50.98M+9.2% vs Q4 2019 Net Income-$121.62M-$121.62MN/M vs Q4 2019 EPS Diluted-$2.37-$2.37N/M vs Q4 2019 Operating Income-$118,550,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Travere Therapeutics, Inc. · CIK 1438533 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$17,711,000N/M Margins · derivedOperating margin-232.5%−172.2 pt vs Q4 2019
Net margin-238.6%−173.7 pt vs Q4 2019
ended Dec 31, 2020 · filed Mar 1, 2021 · 60 d after period end